Bright Minds Biosciences faces an FDA partial clinical hold on its planned BMB-101 Phase 2 DEE study over mouse toxicity and paediatric safety data concerns.
Written By: Kalyani Boharapi, M. Pharm (RA)
Reviewed By: Pharmacally Editorial Team
Bright Minds announced on November 2, 2026, that the US Food and Drug Administration (FDA) had placed its investigational new drug (IND) application for BMB-101 in developmental and epileptic encephalopathies (DEEs), together with the associated Protocol BMB-101-105, on partial clinical hold. The decision follows the agency’s review of the application, with concerns involving toxicity findings in mice and insufficient pharmacokinetic and juvenile toxicity data to support the proposed paediatric enrolment.
FDA Raises Nonclinical Safety Concerns for Planned Phase 2 Study
The affected programme involves a planned randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate ascending doses of BMB-101, up to the maximum tolerated dose, for seizures associated with DEEs.
The FDA identified toxicity findings in mice and inadequate pharmacokinetic and juvenile toxicity data to support the proposed paediatric population. Bright Minds stated that the observed toxicity had not been identified in other species. Based on its toxicity reports, peer reviews and independent toxicology expert opinions, the company considers the mouse findings incidental and not drug-related. However, this represents the company’s assessment and does not resolve the FDA’s stated concerns.
Bright Minds believes the partial clinical hold applies only to the planned US Phase 2 DEE study and does not affect its other ongoing clinical trials. The company is awaiting the FDA’s full Partial Clinical Hold Letter, which the agency indicated would be provided within 30 days. The letter is expected to include additional details, recommendations and study-design guidance.
The company intends to seek clarification from the FDA and refine the study in accordance with the agency’s feedback. Additional data or studies may be required, and there is no assurance regarding when or whether the hold will be lifted.
Previous Clinical Experience with BMB-101
Bright Minds has completed two clinical trials involving BMB-101, with approximately 90 subjects receiving the investigational treatment across its clinical programmes.
In Phase 1, single-ascending-dose, multiple-ascending-dose and food-effect studies were conducted in 64 healthy volunteers. BMB-101 was well tolerated at all tested doses, with no serious adverse events or drug-related serious adverse events. Reported adverse events were mild and consistent with on-target serotonergic effects.
Phase 2 BREAKTHROUGH Trial Reported Antiseizure Activity
On January 6, 2026, Bright Minds announced topline results from its Phase 2 BREAKTHROUGH trial, which enrolled 24 adults with drug-resistant absence seizures or DEE. The study included 15 participants in the absence seizure cohort and nine in the DEE cohort. Most participants were receiving three to five concomitant antiseizure medications.
Among the reported treatment-emergent adverse events, 79.6% were mild and 17.2% were moderate. No treatment-related serious adverse events were reported, although three severe adverse events occurred.
Six efficacy-evaluable patients in the DEE cohort demonstrated a median 63.3% reduction in major motor seizures. The reported reduction was 60.3% among patients with Lennox-Gastaut syndrome and 76.1% among those with other DEEs. These subgroup findings came from very small patient populations and should be interpreted cautiously.
All five DEE patients who entered the open-label extension remained on BMB-101 therapy at the time of the company’s announcement. The reported efficacy and safety findings were preliminary and require further analysis.
Regulatory Outlook and Clinical Significance
The partial clinical hold introduces a nonclinical safety and regulatory hurdle for BMB-101’s planned paediatric development in DEEs. Although earlier Phase 1 and Phase 2 studies reported tolerability and preliminary antiseizure activity, these clinical findings do not address the FDA’s concerns regarding mouse toxicity or the adequacy of pharmacokinetic and juvenile toxicity data.
The next stage of development will depend on the FDA’s detailed recommendations and the additional evidence required to support the proposed study population. The outcome will determine whether protocol modifications or further nonclinical investigations are necessary before the planned Phase 2 programme can proceed.
For Bright Minds, the immediate priority is to address the FDA’s nonclinical safety requirements while clarifying the regulatory pathway for BMB-101’s continued development.
Reference
Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies, Bright Minds, 02 November 2026
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.